Member Info for hangs2left

Over £220 million in gas reserves without the £4million invested to increase this figure

£10 million m/cap is a steal at these prices

UKOG has planning permission to build a wellsite and drill and test one exploratory borehole and a side track near the village of Dunsfold.

The project also includes construction of a new access track, a new road junction and highway improvements.

UKOG announced this morning it had appointed Envoi, an oil and gas divestment and marketing specialist, to facilitate the farmout.

The farmout seeks to fund fully the Loxley drilling and testing programme, UKOG said, with its share of the costs carried by the farminee.

UKOG first announced a farmout at Loxley in July 2022. It said this morning that “active discussions” were also ongoing on a farmout with two energy companies, separately from Envoi’s work.

UKOG’s chief executive, Stephen Sanderson, said if the farmout process were successful it would “remove the requirement for the company to raise additional funds for its share of costs” for the Loxley project.

Https://www.angusenergy.co.uk/malcolm-graham-wood-talks-to-krzysztof-zielicki-non-executive-chairman-of-angus-energy/

A must watch video on Angus website

Labour government. Do any politicians enforce their pre election policies. Uk will be third world country if they kill off oil and gas investments

Coming through now?

Our Deep Geothermal Project provides the baseload generation which wind and solar cannot do without and contains many innovative, risk reducing elements for.

Carbon Capture, Usage and Storage (CCUS) will be a game-changer for the UK’s energy transition. With capacity to safely store up to 78 billion tonnes of CO₂ under our seabed – one of the largest such capacities in the world – we plan to develop CCUS into a highly valuable national asset that will help us reach net zero and boost our economy by up to £5 billion per year by 2050.

We have already decarbonised more than any other major economy since 1990, reducing emissions by nearly half while growing our economy by two thirds. Over the past 13 years, for example, the amount of electricity coming from renewables has increased fivefold. But CCUS gives us new options, such as helping heavy industry to be part of our net zero future, and the UK offering CO₂ storage services to other countries. We have the unique geology, infrastructure and know-how to lead the world in capturing and permanently storing carbon. On top of the environmental benefits, we will capitalise on the economic opportunities of carbon capture and storage.

In March 2023, the Chancellor announced up to £20 billion to support the initial deployment of CCUS. We want to create four CCUS clusters by 2030, storing 20 to 30 megatonnes of CO₂ a year, delivering 50,000 jobs and helping level up the UK. To support this, we have also announced the first eight projects of the ‘first-of-a-kind capture networks’ in North East England, North West England and North Wales, with plans to expand Track-1 clusters and establish Track-2 clusters in North East Scotland and the Humber.

But this is only the start, in this document, we set out a vision of what a market focused CCUS sector might look like, tapping into innovation and business know-how to drive the scale up and acceleration of CCUS deployment during the 2030s. That means creating a competitive market by the middle of the next decade that reduces costs and allows investors to build a thriving and self-sustaining CCUS industry. In this way, the private sector can drive the development of carbon capture, creating jobs and economic growth, and helping us achieve our carbon budget targets.

This is pioneering work, requiring close collaboration between government, industry and local regions where carbon capture clusters are forming. There will be significant challenges as we develop a viable pathway for CCUS, but the rewards will be unprecedented. By investing heavily in the early development of CCUS clusters, and today setting out our longer-term vision for a competitive market, we can meet those challenges and seize those rewards, so CCUS can achieve its full economic opportunity, and the UK can take a giant leap towards net zero.

The survey report was carried out over a year ago

Have they plans on any areas of Intrest in the uk in this field of work?

Maybe join up with sound energy. They wanted Angus for 22 million £s 2 years ago but Angus wanted £35 million. they have m/cap of 17 million

Confirmation Statement

Company Name: ANGUS ENERGY NORTH AMERICA LIMITED

Company Number: 10355604

Received for filing in Electronic Format on the: 29/07/2024 XD8COSNV

Company Name: ANGUS ENERGY NORTH AMERICA LIMITED

Company Number: 10355604

Confirmation

Statement date:

03/07/2024

The company confirms that its intended future activities are lawful.

Electronically filed document for Company Number: 10355604

Confirmation Statement

I confirm that all information required to be delivered by the company to the registrar in relation to

the confirmation period concerned either has been delivered or is being delivered at the same time

5. Use of Proceeds

The net proceeds of the Fundraising (assuming the Minimum Proceeds are raised) are expected to be used as follows.

Approximately 70 per cent. will go towards the following:

· Business development, marketing and support team expansion in the UK, EU and the Middle East increasing the commercial team headcount from seven to eleven

· Pursuing a direct sales model in the U.K. for the MT-RNR1 ID kits

· Marketing, PR, promotions, tradeshows and digital sales channels

· Roll out of the CYP2C19 test in the UK following completion of DEVOTE study and facilitated by final NICE guidance due to be published in July 2024

· Internalisation of manufacturing to permit more efficient scale up of assays as well as onshoring and increased production of instrumentation; and

· Building EU and Middle Eastern distribution network for the Group's CYP2C19 ID kit product following CE-IVD and in country registration process.

Approximately 20 per cent. will go towards U.S. regulatory activities and mid-term product development as detailed below:

· FDA submission process for the MT-RNR1 ID kit test to position for registration and commercialisation in the U.S.;

· Assessing the regulatory pathway and other requirements for potential FDA approval of the CYP2C19 assay;

· Instrumentation enhancements to further facilitate user experience and adoption; and

· Developing version 2 of MT-RNR1 ID kit to include two additional high-risk variants.

Finally, approximately 10 per cent. will go towards the Group's working capital and funding general corporate purposes.

The net proceeds of the Firm Placing will only provide some very short-term working capital for the Company.

9th may rns

Been looking through past RNSs to look for money raised from last placing as to % allocated to FDA process. R&D as I’m sure there was a footnote saying further placing will soon be needed as only 5% was allocated to salary’s office costs

Anyone got a link to this particular RNS?

EMQN CIC[2], a leading global provider of quality assurance tools and knowledge to the human molecular pathology and genomics testing community, is involved in the DEVOTE Programme to ensure the accuracy of the technologies implemented and to develop External Quality Assessment (EQA) schemes for pharmacogenomic POCT.

EMQN CIC’s Pioneering EQA Scheme: EMQN CIC is set to launch an EQA scheme tailored specifically for the Genedrive® MT-RNR1 ID Kit in the autumn of 2024, followed by a pilot for CYP2C19. This groundbreaking initiative is poised to elevate the standards of genomic POCT by providing rigorous quality assessment and fostering continuous improvement. In addition, EMQN CIC will also provide a package of materials to support the validation of POCT machines in situ, currently performed with clinical patient samples.

The Significance of Quality Assurance: While the Point-of-Care devices offer unparalleled convenience and speed, ensuring the accuracy and reliability of test results is of utmost importance. In POCT scenarios, where immediate clinical decisions are based on test outcomes, even the slightest error can have profound consequences. Robust quality assurance measures, such as EMQN CIC’s EQA scheme, are essential to instil confidence in testing outcomes and uphold the integrity of genomic POCT practices.

Moreover, the EMQN CIC test validation package will eliminate the need for extensive patient sample testing, which can be time-consuming, and difficult to achieve due to the frequency of rare gene variants in the population.

Key Features of EMQN CIC’s EQA Schemes for genomic POCT:

Customised Proficiency Testing Materials: EMQN CIC provides bespoke EQA materials using patient derived cell-based swabs, that accurately simulate real-world testing scenarios. These materials are meticulously designed to ensure relevance and accuracy, enabling laboratories to assess their performance in conditions that closely resemble actual clinical settings.

Comprehensive Performance Assessment: The EQA scheme evaluates Genedrive® machines across a spectrum of performance metrics, including sensitivity, specificity, and limit of detection.

Expert Feedback and Guidance: Participating laboratories receive detailed feedback and guidance from EMQN CIC experts, facilitating continuous improvement and best practice adoption.

Benchmarking and Comparative Analysis: The EQA schemes enable benchmarking against POCT centres, fostering a culture of excellence and driving performance enhancement.

Benefits of EMQN CIC’s EQA Schemes for genomic POCT:

Enhanced Accuracy and Reliability: Participation in EMQN CIC’s EQA schemes ensures that testing facilities adhere to rigorous quality standards, thereby enhancing the accuracy and reliability of genomic POCT results.

EMQN EQA schemes support the regulatory process: Participation in EMQN schemes facilitates compliance to regulatory standards (e.g. accreditation to ISO15189:2022).

Facilitate

The Board is pleased with the tangible progress the Group is generating, with a clear focus on pharmacogenetic testing and the commercialisation of our two innovative products. This fuels the Board's optimism for future success, as we strive to generate value for our shareholders while positively impacting individuals' lives.

The news that funding is to be made available from the government's Office for Life Sciences via NIHR for the real world evidence generation required by NICE for our Genedrive® MT-RNR1 ID Kit is very welcome, affording the potential for it to move from a conditional recommendation to a full recommendation with NICE which would accelerate the adoption of the test in the NHS. Genedrive is a technical partner in an application from a consortia of 14 hospitals throughout the UK regions, led by our clinical partners at MFT.

Our equity funding plans are being advanced and the intention will be to raise sufficient funding to complete the clinical trials and regulatory approval process in the USA for the AIHL test whilst also providing sufficient funding to cover the Company's operating costs for an appropriate period of time. The Board intends to provide a mechanism for retail shareholders to participate in any equity financing and a further announcement will be made in due course.

Securing further funding is key to the execution of our strategy as is finalising our partnership in the USA for MT-RNR1 studies required for future de novo submission route for FDA approval. As a direct result of our collaboration with clinical colleagues under the DEVOTE programme for CYP2C19, we should also achieve IVDR approval for CYP2C19 by the end of 2024/early 2025 allowing us to sell the product into Europe and further afield. With both these products, with strong unmet need, clear market potential and defined NICE recommendations, genedrive has significant potential but we will also pursue new developments, partnerships and opportunities for Pharmacogenetic testing. We believe we are in the right place at the right time, with the right products, with little competition in the field of point of care pharmacogenetic testing

I’d expect RNS mid September on sales

Only a month ago did they get Nice recommendation and sales of 5 units two weeks later

Even to now they are still evaluating the devices in hospital triage departments

Sales can only increase. You can say that’s guaranteed

I believe sales of only 18 units a month covers all their operating staff wages costs.

I like to hear about future products they are working on in the POC Pharmacogenetic to compliment their devices. They won’t just have stopped now Nice recommendation and FDA breakthrough device They are doing more than twiddling their thumbs and waiting for sales orders to appear

Key points from a Scientific Statement from the American Heart Association

Clopidogrel is inactive when taken into the body. Activation occurs after the CYP2C19 enzyme has metabolized it. There is genetic variation in CYP2C19 that is linked to the loss of enzymatic function and decreased active clopidogrel metabolite levels, and it varies based on racial and ethnic populations.

A CYP2C19 loss-of-function allele is a variant of the CYP2C19 gene that makes a less functional or nonfunctional enzyme. Compared to non-carriers, CYP2C19 loss-of-function carriers treated with clopidogrel have increased platelet aggregation (platelets clump together). They also have increased blockage of blood flow events, especially after percutaneous coronary intervention, acute coronary syndromes and stroke.

The oral P2Y12 inhibitor drugs ticagrelor or prasugrel are not dependent on CYP2C19 for its activation. CYP2C19 loss-of-function carriers when treated with ticagrelor or prasugrel have significantly reduced cumulative blockage of blood clotting events compared to those treated with clopidogrel. The CYP2C19 genotype is an important determinant of the significant reduction in blood clotting events observed with ticagrelor or prasugrel drug therapy compared to clopidogrel.

Therefore, approximately 70% of patients who do not have the loss-of-function CYP2C19 genetic variants can safely take clopidogrel, while the 30% of patients who do have it can be prescribed alternative drugs such as prasugrel or ticagrelor.

"This precision medicine approach allows physicians to use this information to guide treatment decisions," says Dr. Pereira. "The extensive clinical evidence supports CYP2C19 genetic testing, especially for patients with heart attacks and those who have undergone angioplasty or stent procedures."

Whether clinicians request CYP2C19 genetic testing to guide the use of antiplatelet drugs will depend on several guidelines, including recently published evidence, adoption of point-of-care genetic testing, timely availability of results, integration of results in the electronic health record, education to support understanding and interpretation of results and reimbursement by insurance companies.

A key highlight of 2024 has been Genedrive's collaboration with global healthcare institutions. In June 2024, the company announced a partnership with the World Health Organization (WHO) to provide molecular diagnostics in low-resource settings. This initiative not only underscores Genedrive's commitment to global health but also opens new avenues for market expansion.

Expert Opinions

Industry experts have acknowledged Genedrive's contributions and potential. On July 15th, 2024, a report from Proactive Investors stated, "Genedrive is well-positioned to capitalize on the growing demand for point-of-care diagnostics. Their focus on innovation and strategic partnerships will be key drivers of future growth."

Conclusion

In conclusion, Genedrive PLC has navigated a complex landscape in 2024 with a mix of achievements and challenges. The company's innovative products, strategic partnerships, and commitment to expanding its market reach are promising indicators of future success. While market volatility remains a concern, the long-term outlook for Genedrive appears positive, making it a company to watch closely as it continues to evolve in the rapidly changing healthcare diagnostics sector.

As we move forward, staying informed about Genedrive's developments and market conditions will be crucial for investors. With a focus on innovation and global health, Genedrive is poised to make significant contributions to the healthcare industry, potentially driving substantial value for its stakeholders.

Health care is one of the most important services that need to be provided to any community. Many challenges exist in delivering proper and effective health services, including ensuring timely delivery, providing adequate care through effective management and achieving good outcomes. Point-of-care testing (POCT) plays a crucial role in delivering urgent and appropriate health services, especially in peripheral communities, emergency situations, disaster areas and overcrowded areas. We collected and reviewed secondary data about point-of-care testing from PubMed, Scopus and Google Scholar. Our findings emphasize that POCT provides fast care with minimal waiting time, avoids unnecessary investigations, aids in triage, and provides decision-makers with a clear understanding of the patient’s condition to make informed decisions. We recommend point-of-care testing as a frontline investigation in emergency departments, intensive care units, peripheral hospitals, primary health care centers, disaster areas and field hospitals. Point-of-care testing can improve the quality of health services and ensure the provision of necessary health care.

Keywords: patient triage, early deposition, early management, early diagnosis, overcrowded, waiting time, short stay, turnaround time (tat), point of care testing

Go to:

Introduction and background

Point-of-care (POC) testing (POCT) refers to simple or non-invasive diagnostic tests that are conducted near the patients, eliminating the need to send samples to a central lab or tertiary hospital for analysis. The point-of-care procedure is characterized by a swift turnaround time, often yielding results within a few minutes. Any simple and non-invasive diagnostic test or procedure that is administered near the patient can be classified as point-of-care [1,2].

POCT can be used in emergency departments (EDs), intensive care units (ICUs), acute care services, primary health care, pre-hospital settings, rural hospitals, mobile medical